Wayne Old, MD
Advanced Heart Failure and Transplant Cardiology · Chesapeake, VANPI 1336115799
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,326 of the $1,690 with a category attached, or 78.5%. 11 manufacturers reported payments, led by Abbott at 30.8% of the total. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in VA, where the typical reported total is $4,498.
Across 19 payments — averaging $88.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$521
- Vifor Pharma, Inc.$200
- Nuwellis, Inc.$198
- Akcea Therapeutics, Inc.$150
- Bridgebio Pharma, Inc.$135
- Esperion Therapeutics, Inc.$123
- plus $364 from 5 others
Across 106 payments — averaging $2621.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$130K
- Boehringer Ingelheim International GmbH$80K
- American Regent$36K
- Boehringer Ingelheim Pharma GmbH & Co.kg$22K
- Vifor (international) Ltd.$10K
What the payments were for
- Speaking & faculty fees$35021%
- Food & beverage$1,32678%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 6 | $521 |
| Vifor Pharma, Inc. | 1 | $200 |
| Nuwellis, Inc. | 1 | $198 |
| Akcea Therapeutics, Inc. | 1 | $150 |
| Bridgebio Pharma, Inc. | 1 | $135 |
| Esperion Therapeutics, Inc. | 1 | $123 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Boehringer Ingelheim | 1 | $116 |
| Abiomed | 2 | $74 |
| Astellas Pharma US Inc | 3 | $41 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$284
- Veltassa$200
- AQUADEX SMARTFLOW CONSOLE$198
- TEGSEDI$150
- JETi Peripheral Catheter$142
- Attruby$135
- NEXLIZET$123
- NEXLETOL$123
- CAMZYOS$119
How this compares
$1,690 in reported general payments places this provider in the 25th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
See all advanced heart failure and transplant cardiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 378 | $403,820 |
| VyndamaxTafamidis | 16 | $347,880 |
| CamzyosMavacamten | 34 | $268,689 |
| JardianceEmpagliflozin | 228 | $224,912 |
| EliquisApixaban | 204 | $200,636 |
| FarxigaDapagliflozin Propanediol | 98 | $92,595 |
| Repatha SureclickEvolocumab | 49 | $36,142 |
| XareltoRivaroxaban | 31 | $28,812 |
| Sirolimus | 14 | $6,227 |
| Metoprolol Succinate | 262 | $4,962 |
| Eplerenone | 26 | $2,449 |
| Spironolactone | 341 | $2,433 |
| Bumetanide | 60 | $2,345 |
| Carvedilol | 260 | $2,303 |
| Isosorbide Dinitrate | 34 | $1,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $119 | $268,68934 claims |
| Boehringer IngelheimJardiance | $116 | $224,912228 claims |
| AstraZenecaFarxiga | $14 | $92,59598 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
Other advanced heart failure and transplant cardiology in Chesapeake
- John HerreChesapeake$270K
- Frank AmicoChesapeake$19K
- Amin YehyaNorfolk$398K
- Raymond BenzaNorfolk$141K
- Palak ShahFalls Church$112K
- Zackary TushakNorfolk$92K
- Shashank DesaiFalls Church$80K
- Keyur ShahRichmond,$62K
- Mirnela BykuCharlottesville$62K
- Edward SaweyRichmond$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.